Dermira (NASDAQ:DERM) Trading Down 7.3%

Dermira Inc (NASDAQ:DERM) shares traded down 7.3% during trading on Wednesday . The company traded as low as $8.76 and last traded at $8.91. 1,358,080 shares were traded during trading, a decline of 6% from the average session volume of 1,445,143 shares. The stock had previously closed at $9.61.

A number of research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Dermira from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Tuesday, May 7th. BidaskClub lowered shares of Dermira from a “sell” rating to a “strong sell” rating in a research report on Friday, June 7th. Cantor Fitzgerald boosted their price target on shares of Dermira to $25.00 and gave the company an “overweight” rating in a research report on Thursday, April 18th. HC Wainwright restated a “buy” rating on shares of Dermira in a research report on Wednesday, May 8th. Finally, Mizuho upgraded shares of Dermira from a “neutral” rating to a “buy” rating and reduced their price target for the company from $17.00 to $14.00 in a research report on Thursday, June 6th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Dermira currently has a consensus rating of “Buy” and a consensus target price of $17.97.

The business has a 50-day simple moving average of $9.92. The company has a market cap of $510.38 million, a P/E ratio of -1.70 and a beta of 1.40. The company has a quick ratio of 6.92, a current ratio of 7.13 and a debt-to-equity ratio of 4.36.

Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.39). Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%. The company had revenue of $2.45 million during the quarter, compared to analysts’ expectations of $2.63 million. Sell-side analysts forecast that Dermira Inc will post -5.2 EPS for the current fiscal year.

In related news, insider Eugene A. Bauer sold 35,000 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the transaction, the insider now directly owns 43,900 shares in the company, valued at $658,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.40% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in Dermira by 469.9% during the fourth quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock valued at $15,619,000 after buying an additional 1,791,178 shares during the period. Vivo Capital LLC purchased a new stake in Dermira during the first quarter valued at about $9,485,000. Rhenman & Partners Asset Management AB purchased a new stake in Dermira during the first quarter valued at about $6,779,000. Candriam Luxembourg S.C.A. purchased a new stake in Dermira during the first quarter valued at about $4,743,000. Finally, Jacobs Levy Equity Management Inc. boosted its position in Dermira by 68.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock valued at $10,347,000 after buying an additional 310,551 shares during the period. Institutional investors own 93.92% of the company’s stock.

About Dermira (NASDAQ:DERM)

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Read More: Support Level

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.